Clinical Cancer Research, Vol 4, Issue 5 1305-1314, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts

AM Al-Katib, MR Smith, WS Kamanda, GR Pettit, M Hamdan, AN Mohamed, B Chelladurai and RM Mohammad
Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.

The down-regulation of multidrug resistance (mdr1) gene expression as detected by competitive reverse transcription-PCR and the antitumor activity of bryostatin 1 (Bryo1) are investigated in a newly established cell line from a patient with relapsed diffuse large cell lymphoma (DLCL). The cell line (WSU-DLCL2) grows in liquid culture and forms s.c. tumors in mice with severe combined immune deficiency. WSU-DLCL2 is a mature B-cell line (IgG lambda) that is negative for EBV nuclear antigen, expresses the multidrug resistance phenotype, and has t(14;18)(q32;q21) plus other chromosomal aberrations. Exposure of the WSU-DLCL2 cells to Bryo1 in culture reversed the multidrug resistance phenotype within 24 h. A functional assay revealed a 4-fold increase in [3H]vincristine accumulation in Bryo1-treated cells compared with control. Vincristine (VCR), doxorubicin, Bryo1, and 1-beta-D-arabinofuranosylcytosine showed no clinically significant activity when given alone to WSU-DLCL2-bearing severe combined immune deficiency mice. However, when given 24 h before each cytotoxic agent, Bryo1 substantially increased the antitumor activity of VCR but not 1-beta-D-arabinofuranosylcytosine. There was a statistically significant (P < 0.001) decrease in the expression of P-glycoprotein in WSU-DLCL2 tumors taken from Bryo1-treated animals compared with untreated controls. In vivo, a competitive reverse transcription-PCR assay revealed decreased mdr1 RNA expression 24 h after Bryo1 treatment. These findings taken together indicate that Bryo1-induced down-regulation of mdr1 might be one mechanism by which Bryo1 potentiates VCR activity. The sequential use of both agents resulted in clinically significant antitumor activity in this lymphoma model.

This article has been cited by other articles:

				R. M. Mohammad, A. S. Goustin, A. Aboukameel, B. Chen, S. Banerjee, G. Wang, Z. Nikolovska-Coleska, S. Wang, and A. Al-Katib Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1 Clin. Cancer Res., April 1, 2007; 13(7): 2226 - 2235. [Abstract] [Full Text] [PDF]

				J. D. Roberts, M. R. Smith, E. J. Feldman, L. Cragg, M. M. Millenson, G. J. Roboz, C. Honeycutt, R. Thune, K. Padavic-Shaller, W. H. Carter, et al. Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma. Clin. Cancer Res., October 1, 2006; 12(19): 5809 - 5816. [Abstract] [Full Text] [PDF]

				R. M. Mohammad, S. Wang, A. Aboukameel, B. Chen, X. Wu, J. Chen, and A. Al-Katib Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL [(-)-gossypol] against diffuse large cell lymphoma Mol. Cancer Ther., January 1, 2005; 4(1): 13 - 21. [Abstract] [Full Text] [PDF]

				A. Dowlati, H. M. Lazarus, P. Hartman, J. W. Jacobberger, C. Whitacre, S. L. Gerson, P. Ksenich, B. W. Cooper, P. S. Frisa, M. Gottlieb, et al. Phase I and Correlative Study of Combination Bryostatin 1 and Vincristine in Relapsed B-Cell Malignancies Clin. Cancer Res., December 1, 2003; 9(16): 5929 - 5935. [Abstract] [Full Text] [PDF]

				R. M. Mohammad, A. Al-Katib, A. Aboukameel, D. R. Doerge, F. Sarkar, and O. Kucuk Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy Mol. Cancer Ther., December 1, 2003; 2(12): 1361 - 1368. [Abstract] [Full Text] [PDF]

				A. Kanzaki, Y. Takebayashi, X.-Q. Ren, H. Miyashita, S. Mori, S.-i. Akiyama, and Y. Pommier Overcoming Multidrug Drug Resistance in P-Glycoprotein/MDR1-overexpressing Cell Lines by Ecteinascidin 743 Mol. Cancer Ther., December 1, 2002; 1(14): 1327 - 1334. [Abstract] [Full Text] [PDF]

				J. A. Zonder, A. F. Shields, M. Zalupski, R. Chaplen, L. K. Heilbrun, P. Arlauskas, and P. A. Philip A Phase II Trial of Bryostatin 1 in the Treatment of Metastatic Colorectal Cancer Clin. Cancer Res., January 1, 2001; 7(1): 38 - 42. [Abstract] [Full Text]

				R. M. Mohammad, N. R. Wall, J. A. Dutcher, and A. M. Al-Katib The Addition of Bryostatin 1 to Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Chemotherapy Improves Response in a CHOP-resistant Human Diffuse Large Cell Lymphoma Xenograft Model Clin. Cancer Res., December 1, 2000; 6(12): 4950 - 4956. [Abstract] [Full Text]

				M. L. Varterasian, R. M. Mohammad, M. S. Shurafa, K. Hulburd, P. A. Pemberton, D. H. Rodriguez, V. Spadoni, D. S. Eilender, A. Murgo, N. Wall, et al. Phase II Trial of Bryostatin 1 in Patients with Relapsed Low-Grade Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Clin. Cancer Res., March 1, 2000; 6(3): 825 - 828. [Abstract] [Full Text]

				S. Weitman, A.-M. Langevin, R. L. Berkow, P. J. Thomas, C. A. Hurwitz, A. S. Kraft, R. L. Dubowy, D. L. Smith, and M. Bernstein A Phase I Trial of Bryostatin-1 in Children with Refractory Solid Tumors: A Pediatric Oncology Group Study Clin. Cancer Res., September 1, 1999; 5(9): 2344 - 2348. [Abstract] [Full Text] [PDF]